<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">36788520</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>16</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1479-5876</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of translational medicine</Title><ISOAbbreviation>J Transl Med</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of first-in-man intrathecal injection of human astrocytes (AstroRx&#xae;) in ALS patients: phase I/IIa clinical trial results.</ArticleTitle><Pagination><StartPage>122</StartPage><MedlinePgn>122</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">122</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12967-023-03903-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Malfunction of astrocytes is implicated as one of the pathological factors of ALS. Thus, intrathecal injection of healthy astrocytes in ALS can potentially compensate for the diseased astrocytes. AstroRx&#xae; is an allogeneic cell-based product, composed of healthy and functional human astrocytes derived from embryonic stem cells. AstroRx&#xae; was shown to clear excessive glutamate, reduce oxidative stress, secrete various neuroprotective factors, and act as an immunomodulator. Intrathecal injection of AstroRx&#xae; to animal models of ALS slowed disease progression and extended survival. Here we report the result of a first-in-human clinical study evaluating intrathecal injection of AstroRx&#xae; in ALS patients.</AbstractText><AbstractText Label="METHODS">We conducted a phase I/IIa, open-label, dose-escalating clinical trial to evaluate the safety, tolerability, and therapeutic effects of intrathecal injection of AstroRx&#xae; in patients with ALS. Five patients were injected intrathecally with a single dose of 100&#x2009;&#xd7;&#x2009;10<sup>6</sup> AstroRx&#xae; cells and 5 patients with 250&#x2009;&#xd7;&#x2009;10<sup>6</sup> cells (low and high dose, respectively). Safety and efficacy assessments were recorded for 3&#xa0;months pre-treatment (run-in period) and 12&#xa0;months post-treatment (follow-up period).</AbstractText><AbstractText Label="RESULTS">A single administration of AstroRx&#xae; at either low or high doses was safe and well tolerated. No adverse events (AEs) related to AstroRx&#xae; itself were reported. Transient AEs related to the Intrathecal (IT) procedure were all mild to moderate. The study demonstrated a clinically meaningful effect that was maintained over the first 3&#xa0;months after treatment, as measured by the pre-post slope change in ALSFRS-R. In the 100&#x2009;&#xd7;&#x2009;10<sup>6</sup> AstroRx&#xae; arm, the ALSFRS-R rate of deterioration was attenuated from -&#xa0;0.88/month pre-treatment to -&#xa0;0.30/month in the first 3&#xa0;months post-treatment (p&#x2009;=&#x2009;0.039). In the 250&#x2009;&#xd7;&#x2009;10<sup>6</sup> AstroRx&#xae; arm, the ALSFRS-R slope decreased from -&#xa0;1.43/month to -&#xa0;0.78/month (p&#x2009;=&#x2009;0.0023). The effect was even more profound in a rapid progressor subgroup of 5 patients. No statistically significant change was measured in muscle strength using hand-held dynamometry and slow vital capacity continued to deteriorate during the study.</AbstractText><AbstractText Label="CONCLUSIONS">Overall, these findings suggest that a single IT administration of AstroRx&#xae; to ALS patients at a dose of 100&#x2009;&#xd7;&#x2009;10<sup>6</sup> or 250&#x2009;&#xd7;&#x2009;10<sup>6</sup> cells is safe. A signal of beneficial clinical effect was observed for the first 3&#xa0;months following cell injection. These results support further investigation of repeated intrathecal administrations of AstroRx&#xae;, e.g., every 3&#xa0;months.</AbstractText><AbstractText Label="TRIAL REGISTRATION">NCT03482050.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Caraco</LastName><ForeName>Yoseph</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hadassah Clinical Research Center (HCRC), Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lerner</LastName><ForeName>Yossef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blotnick</LastName><ForeName>Simcha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hadassah Clinical Research Center (HCRC), Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wanounou</LastName><ForeName>Maor</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hadassah Clinical Research Center (HCRC), Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slutsky</LastName><ForeName>Shalom Guy</ForeName><Initials>SG</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chebath</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuperstein</LastName><ForeName>Graciela</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Estrin</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Hur</LastName><ForeName>Tamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hasson</LastName><ForeName>Arik</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molakandov</LastName><ForeName>Kfir</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sonnenfeld</LastName><ForeName>Tehila</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stark</LastName><ForeName>Yafit</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revel</LastName><ForeName>Ariel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Revel</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Molecular Genetics, Weizmann Institute of Science, 76100, Rehovot, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Izrael</LastName><ForeName>Michal</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2937-9961</Identifier><AffiliationInfo><Affiliation>Neurodegenerative Diseases Department, Kadimastem Ltd, Pinchas Sapir 7, Weizmann Science Park, Ness-Ziona, Israel. M.izrael@kadimastem.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT03482050</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Transl Med</MedlineTA><NlmUniqueID>101190741</NlmUniqueID><ISSNLinking>1479-5876</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001253" MajorTopicYN="N">Astrocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007278" MajorTopicYN="N">Injections, Spinal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Astrocytes</Keyword><Keyword MajorTopicYN="N">Cell therapy</Keyword><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Intrathecal injection</Keyword></KeywordList><CoiStatement>The authors declare that they have no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36788520</ArticleId><ArticleId IdType="pmc">PMC9927047</ArticleId><ArticleId IdType="doi">10.1186/s12967-023-03903-3</ArticleId><ArticleId IdType="pii">10.1186/s12967-023-03903-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344(22):1688&#x2013;1700. doi: 10.1056/NEJM200105313442207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200105313442207</ArticleId><ArticleId IdType="pubmed">11386269</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2013;1431. doi: 10.1016/S0140-6736(96)91680-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)91680-3</ArticleId><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2013;591. doi: 10.1056/NEJM199403033300901.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K. An early history of Japanese amyotrophic lateral sclerosis (ALS) and the current significance. Rinsho Shinkeigaku. 2017;57(4):153&#x2013;162. doi: 10.5692/clinicalneurol.cn-001000.</Citation><ArticleIdList><ArticleId IdType="doi">10.5692/clinicalneurol.cn-001000</ArticleId><ArticleId IdType="pubmed">28367949</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185&#x2013;193. doi: 10.1080/14737175.2019.1581610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1581610</ArticleId><ArticleId IdType="pubmed">30810406</ArticleId></ArticleIdList></Reference><Reference><Citation>Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, Karam C, Caress JB, Owegi MA, Quick A, Wymer J, Goutman SA, Heitzman D, Heiman-Patterson T, Jackson CE, Quinn C, Rothstein JD, Kasarskis EJ, Katz J, Jenkins L, Ladha S, Miller TM, Scelsa SN, Vu TH, Fournier CN, Glass JD, Johnson KM, Swenson A, Goyal NA, Pattee GL, Andres PL, Babu S, Chase M, Dagostino D, Dickson SP, Ellison N, Hall M, Hendrix K, Kittle G, McGovern M, Ostrow J, Pothier L, Randall R, Shefner JM, Sherman AV, Tustison E, Vigneswaran P, Walker J, Yu H, Chan J, Wittes J, Cohen J, Klee J, Leslie K, Tanzi RE, Gilbert W, Yeramian PD, Schoenfeld D, Cudkowicz ME. Trial of sodium phenylbutyrate-taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383(10):919&#x2013;930. doi: 10.1056/NEJMoa1916945.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1916945</ArticleId><ArticleId IdType="pmc">PMC9134321</ArticleId><ArticleId IdType="pubmed">32877582</ArticleId></ArticleIdList></Reference><Reference><Citation>Johann S. Astrocytes pathology in ALS: a potential therapeutic target? Curr Pharm Des. 2017;23(33):5022&#x2013;5036.</Citation><ArticleIdList><ArticleId IdType="pubmed">28619000</ArticleId></ArticleIdList></Reference><Reference><Citation>Izrael M, Slutsky SG, Revel M. Rising stars: astrocytes as a therapeutic target for ALS disease. Front Neurosci. 2020;14:824. doi: 10.3389/fnins.2020.00824.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00824</ArticleId><ArticleId IdType="pmc">PMC7399224</ArticleId><ArticleId IdType="pubmed">32848579</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen NJ, Eroglu C. Cell biology of astrocyte-synapse interactions. Neuron. 2017;96(3):697&#x2013;708. doi: 10.1016/j.neuron.2017.09.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2017.09.056</ArticleId><ArticleId IdType="pmc">PMC5687890</ArticleId><ArticleId IdType="pubmed">29096081</ArticleId></ArticleIdList></Reference><Reference><Citation>Verkhratsky A, Zorec R, Parpura V. Stratification of astrocytes in healthy and diseased brain. Brain Pathol. 2017;27(5):629&#x2013;644. doi: 10.1111/bpa.12537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12537</ArticleId><ArticleId IdType="pmc">PMC5599174</ArticleId><ArticleId IdType="pubmed">28805002</ArticleId></ArticleIdList></Reference><Reference><Citation>Fasciani I, Pluta P, Gonzalez-Nieto D, Martinez-Montero P, Molano J, Paino CL, Millet O, Barrio LC. Directional coupling of oligodendrocyte connexin-47 and astrocyte connexin-43 gap junctions. Glia. 2018;66(11):2340&#x2013;2352. doi: 10.1002/glia.23471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23471</ArticleId><ArticleId IdType="pubmed">30144323</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017;46(6):957&#x2013;967. doi: 10.1016/j.immuni.2017.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2017.06.006</ArticleId><ArticleId IdType="pubmed">28636962</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Komine O. The multi-dimensional roles of astrocytes in ALS. Neurosci Res. 2018;126:31&#x2013;38. doi: 10.1016/j.neures.2017.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2017.09.011</ArticleId><ArticleId IdType="pubmed">29054467</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Harten ACM, Phatnani H, Przedborski S. Non-cell-autonomous pathogenic mechanisms in amyotrophic lateral sclerosis. Trends Neurosci. 2021;44(8):658&#x2013;668. doi: 10.1016/j.tins.2021.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2021.04.008</ArticleId><ArticleId IdType="pmc">PMC8972039</ArticleId><ArticleId IdType="pubmed">34006386</ArticleId></ArticleIdList></Reference><Reference><Citation>Crabe R, Aimond F, Gosset P, Scamps F, Raoul C. How degeneration of cells surrounding motoneurons contributes to amyotrophic lateral sclerosis. Cells. 2020;9(12):2550. doi: 10.3390/cells9122550.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9122550</ArticleId><ArticleId IdType="pmc">PMC7760029</ArticleId><ArticleId IdType="pubmed">33260927</ArticleId></ArticleIdList></Reference><Reference><Citation>Smethurst P, Risse E, Tyzack GE, Mitchell JS, Taha DM, Chen YR, Newcombe J, Collinge J, Sidle K, Patani R. Distinct responses of neurons and astrocytes to TDP-43 proteinopathy in amyotrophic lateral sclerosis. Brain. 2020;143(2):430&#x2013;440. doi: 10.1093/brain/awz419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz419</ArticleId><ArticleId IdType="pmc">PMC7009461</ArticleId><ArticleId IdType="pubmed">32040555</ArticleId></ArticleIdList></Reference><Reference><Citation>Reichardt LF. Neurotrophin-regulated signalling pathways. Philos Trans R Soc Lond B Biol Sci. 2006;361(1473):1545&#x2013;1564. doi: 10.1098/rstb.2006.1894.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rstb.2006.1894</ArticleId><ArticleId IdType="pmc">PMC1664664</ArticleId><ArticleId IdType="pubmed">16939974</ArticleId></ArticleIdList></Reference><Reference><Citation>Poyhonen S, Er S, Domanskyi A, Airavaara M. Effects of neurotrophic factors in glial cells in the central nervous system: expression and properties in neurodegeneration and injury. Front Physiol. 2019;10:486. doi: 10.3389/fphys.2019.00486.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphys.2019.00486</ArticleId><ArticleId IdType="pmc">PMC6499070</ArticleId><ArticleId IdType="pubmed">31105589</ArticleId></ArticleIdList></Reference><Reference><Citation>Izrael M, Slutsky SG, Admoni T, Cohen L, Granit A, Hasson A, Itskovitz-Eldor J, Krush Paker L, Kuperstein G, Lavon N, Yehezkel Ionescu S, Solmesky LJ, Zaguri R, Zhuravlev A, Volman E, Chebath J, Revel M. Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models. Stem Cell Res Ther. 2018;9(1):152. doi: 10.1186/s13287-018-0890-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-018-0890-5</ArticleId><ArticleId IdType="pmc">PMC5989413</ArticleId><ArticleId IdType="pubmed">29871694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K, Chun SJ, Boillee S, Fujimori-Tonou N, Yamashita H, Gutmann DH, Takahashi R, Misawa H, Cleveland DW. Astrocytes as determinants of disease progression in inherited amyotrophic lateral sclerosis. Nat Neurosci. 2008;11(3):251&#x2013;253. doi: 10.1038/nn2047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nn2047</ArticleId><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Funayama M, Tsukita K, Hotta A, Yasuda A, Nori S, Kaneko S, Nakamura M, Takahashi R, Okano H, Yamanaka S, Inoue H. Focal transplantation of human iPSC-derived glial-rich neural progenitors improves lifespan of ALS mice. Stem cell reports. 2014;3(2):242&#x2013;249. doi: 10.1016/j.stemcr.2014.05.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stemcr.2014.05.017</ArticleId><ArticleId IdType="pmc">PMC4175543</ArticleId><ArticleId IdType="pubmed">25254338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lepore AC, Dejea C, Carmen J, Rauck B, Kerr DA, Sofroniew MV, Maragakis NJ. Selective ablation of proliferating astrocytes does not affect disease outcome in either acute or chronic models of motor neuron degeneration. Exp Neurol. 2008;211(2):423&#x2013;432. doi: 10.1016/j.expneurol.2008.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.02.020</ArticleId><ArticleId IdType="pmc">PMC9152669</ArticleId><ArticleId IdType="pubmed">18410928</ArticleId></ArticleIdList></Reference><Reference><Citation>Izrael M, Slutsky S, Itskovitz-Eldor J, Revel M. Astrocytes in pathogenesis of neurodegenerative diseases and potential: translation into clinic. InTechOpen: Astrocyte&#x2014;Physiology and Pathology 2018. ISBN 978-953-51-5760-1, 93&#x2013;118.</Citation></Reference><Reference><Citation>Liu G, David BT, Trawczynski M, Fessler RG. Advances in pluripotent stem cells: history, mechanisms, technologies, and applications. Stem Cell Rev Rep. 2020;16(1):3&#x2013;32. doi: 10.1007/s12015-019-09935-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12015-019-09935-x</ArticleId><ArticleId IdType="pmc">PMC6987053</ArticleId><ArticleId IdType="pubmed">31760627</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Genge A, Chio A, Estol CJ, Chaverri D, Hernandez M, Marin S, Mascias J, Rodriguez GE, Povedano M, Paipa A, Dominguez R, Gamez J, Salvado M, Lunetta C, Ballario C, Riva N, Mandrioli J, Moussy A, Kinet JP, Auclair C, Dubreuil P, Arnold V, Mansfield CD, Hermine O, Ab10015 Study, G Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21(1&#x2013;2):5&#x2013;14. doi: 10.1080/21678421.2019.1632346.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1632346</ArticleId><ArticleId IdType="pubmed">31280619</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry. 2016;87(6):628&#x2013;632. doi: 10.1136/jnnp-2015-310998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2015-310998</ArticleId><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009;4:3. doi: 10.1186/1750-1172-4-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1172-4-3</ArticleId><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Forgrave LM, Ma M, Best JR, DeMarco ML. The diagnostic performance of neurofilament light chain in CSF and blood for Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis: a systematic review and meta-analysis. Alzheimers Dement (Amst) 2019;11:730&#x2013;743. doi: 10.1016/j.dadm.2019.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dadm.2019.08.009</ArticleId><ArticleId IdType="pmc">PMC6939029</ArticleId><ArticleId IdType="pubmed">31909174</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou YN, Chen YH, Dong SQ, Yang WB, Qian T, Liu XN, Cheng Q, Wang JC, Chen XJ. Role of blood neurofilaments in the prognosis of amyotrophic lateral sclerosis: a meta-analysis. Front Neurol. 2021;12:712245. doi: 10.3389/fneur.2021.712245.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2021.712245</ArticleId><ArticleId IdType="pmc">PMC8526968</ArticleId><ArticleId IdType="pubmed">34690913</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde F, Otto M, Silani V. Neurofilament light chain as biomarker for amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci. 2021;15:679199. doi: 10.3389/fnins.2021.679199.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2021.679199</ArticleId><ArticleId IdType="pmc">PMC8255624</ArticleId><ArticleId IdType="pubmed">34234641</ArticleId></ArticleIdList></Reference><Reference><Citation>Halbgebauer S, Steinacker P, Verde F, Weishaupt J, Oeckl P, von Arnim C, Dorst J, Feneberg E, Mayer B, Rosenbohm A, Silani V, Ludolph AC, Otto M. Comparison of CSF and serum neurofilament light and heavy chain as differential diagnostic biomarkers for ALS. J Neurol Neurosurg Psychiatry. 2022;93(1):68&#x2013;74. doi: 10.1136/jnnp-2021-327129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2021-327129</ArticleId><ArticleId IdType="pubmed">34417339</ArticleId></ArticleIdList></Reference><Reference><Citation>Witzel S, Frauhammer F, Steinacker P, Devos D, Pradat PF, Meininger V, Halbgebauer S, Oeckl P, Schuster J, Anders S, Dorst J, Otto M, Ludolph AC. Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials. Transl Neurodegener. 2021;10(1):31. doi: 10.1186/s40035-021-00257-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-021-00257-y</ArticleId><ArticleId IdType="pmc">PMC8390195</ArticleId><ArticleId IdType="pubmed">34433481</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JH, Chung JY, Yoo DY, Hwang IK, Yoo KY, Lee CH, Yan BC, Ahn JO, Youn HY, Won MH. Cell proliferation and neuroblast differentiation in the rat dentate gyrus after intrathecal treatment with adipose-derived mesenchymal stem cells. Cell Mol Neurobiol. 2011;31(8):1271&#x2013;1280. doi: 10.1007/s10571-011-9729-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10571-011-9729-7</ArticleId><ArticleId IdType="pubmed">21710253</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing G, Edaravone ALSSG. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505&#x2013;512. doi: 10.1016/S1474-4422(17)30115-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Harris TH, Kipnis J. Revisiting the mechanisms of CNS immune privilege. Trends Immunol. 2015;36(10):569&#x2013;577. doi: 10.1016/j.it.2015.08.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2015.08.006</ArticleId><ArticleId IdType="pmc">PMC4593064</ArticleId><ArticleId IdType="pubmed">26431936</ArticleId></ArticleIdList></Reference><Reference><Citation>Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015;523(7560):337&#x2013;341. doi: 10.1038/nature14432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature14432</ArticleId><ArticleId IdType="pmc">PMC4506234</ArticleId><ArticleId IdType="pubmed">26030524</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzini L, Gelati M, Profico DC, Sgaravizzi G, Projetti Pensi M, Muzi G, Ricciolini C, Rota Nodari L, Carletti S, Giorgi C, Spera C, Domenico F, Bersano E, Petruzzelli F, Cisari C, Maglione A, Sarnelli MF, Stecco A, Querin G, Masiero S, Cantello R, Ferrari D, Zalfa C, Binda E, Visioli A, Trombetta D, Novelli A, Torres B, Bernardini L, Carriero A, Prandi P, Servo S, Cerino A, Cima V, Gaiani A, Nasuelli N, Massara M, Glass J, Soraru G, Boulis NM, Vescovi AL. Human neural stem cell transplantation in ALS: initial results from a phase I trial. J Transl Med. 2015;13:17. doi: 10.1186/s12967-014-0371-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-014-0371-2</ArticleId><ArticleId IdType="pmc">PMC4359401</ArticleId><ArticleId IdType="pubmed">25889343</ArticleId></ArticleIdList></Reference><Reference><Citation>Tadesse T, Gearing M, Senitzer D, Saxe D, Brat DJ, Bray R, Gebel H, Hill C, Boulis N, Riley J, Feldman E, Johe K, Hazel T, Polak M, Bordeau J, Federici T, Glass JD. Analysis of graft survival in a trial of stem cell transplant in ALS. Ann Clin Transl Neurol. 2014;1(11):900&#x2013;908. doi: 10.1002/acn3.134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.134</ArticleId><ArticleId IdType="pmc">PMC4265061</ArticleId><ArticleId IdType="pubmed">25540804</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado-Manzano C, Perpina U, Straccia M, Molina-Ruiz FJ, Cozzi E, Rosser AE, Canals JM. Is the immunological response a bottleneck for cell therapy in neurodegenerative diseases? Front Cell Neurosci. 2020;14:250. doi: 10.3389/fncel.2020.00250.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2020.00250</ArticleId><ArticleId IdType="pmc">PMC7433375</ArticleId><ArticleId IdType="pubmed">32848630</ArticleId></ArticleIdList></Reference><Reference><Citation>Appel SH, Stewart SS, Appel V, Harati Y, Mietlowski W, Weiss W, Belendiuk GW. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch Neurol. 1988;45(4):381&#x2013;386. doi: 10.1001/archneur.1988.00520280027011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.1988.00520280027011</ArticleId><ArticleId IdType="pubmed">3281637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fournier CN, Schoenfeld D, Berry JD, Cudkowicz ME, Chan J, Quinn C, Brown RH, Salameh JS, Tansey MG, Beers DR, Appel SH, Glass JD. An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(3&#x2013;4):242&#x2013;249. doi: 10.1080/21678421.2017.1421666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1421666</ArticleId><ArticleId IdType="pubmed">29308669</ArticleId></ArticleIdList></Reference><Reference><Citation>Glass JD, Boulis NM, Johe K, Rutkove SB, Federici T, Polak M, Kelly C, Feldman EL. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells. 2012;30(6):1144&#x2013;1151. doi: 10.1002/stem.1079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/stem.1079</ArticleId><ArticleId IdType="pubmed">22415942</ArticleId></ArticleIdList></Reference><Reference><Citation>Gordon PH, Cheng B, Salachas F, Pradat PF, Bruneteau G, Corcia P, Lacomblez L, Meininger V. Progression in ALS is not linear but is curvilinear. J Neurol. 2010;257(10):1713&#x2013;1717. doi: 10.1007/s00415-010-5609-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-010-5609-1</ArticleId><ArticleId IdType="pubmed">20532545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy D, Severson K, Ghosh S, Sachs K, Glass JD, Fournier CN, Pooled Resource Open-Access ALS Clinical Trials Consortium, ALS/MND Natural History Consortium, Todd M, Berry JD, Kenney NG, Fraenkel E. Identifying patterns in amyotrophic lateral sclerosis progression from sparse longitudinal data. Nat Comput Sci 2022; 2: 605&#x2013;616.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>